Since Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation of both companies.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics Inc.	N/A	0.00	230.70M	-5.23	0.00
Alder BioPharmaceuticals Inc.	N/A	0.00	331.93M	-4.88	0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Atara Biotherapeutics Inc. and Alder BioPharmaceuticals Inc.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both businesses.

	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics Inc.	0.00%	-56.5%	-51.2%
Alder BioPharmaceuticals Inc.	0.00%	-158.8%	-64.1%

Volatility & Risk

Atara Biotherapeutics Inc.’s current beta is 2.23 and it happens to be 123.00% more volatile than Standard and Poor’s 500. Alder BioPharmaceuticals Inc. has a 2.78 beta and it is 178.00% more volatile than Standard and Poor’s 500.

Analyst Recommendations

In next table is delivered Atara Biotherapeutics Inc. and Alder BioPharmaceuticals Inc.’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Atara Biotherapeutics Inc.	0	0	2	3.00
Alder BioPharmaceuticals Inc.	0	3	5	2.63

The average price target of Atara Biotherapeutics Inc. is $66, with potential upside of 65.33%. Meanwhile, Alder BioPharmaceuticals Inc.’s average price target is $20.14, while its potential upside is 45.31%. Based on the analysts opinion we can conclude, Atara Biotherapeutics Inc. is looking more favorable than Alder BioPharmaceuticals Inc.

Insider & Institutional Ownership

Insiders owned 2.7% of Atara Biotherapeutics Inc. shares. Comparatively, insiders own roughly 0.4% of Alder BioPharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Atara Biotherapeutics Inc.	-6.76%	2.42%	-2.06%	-2.7%	4.62%	12.03%
Alder BioPharmaceuticals Inc.	-11.9%	-7.95%	-3.14%	-27.8%	-6.43%	26.44%

For the past year Atara Biotherapeutics Inc.’s stock price has smaller growth than Alder BioPharmaceuticals Inc.

Summary

Atara Biotherapeutics Inc. beats Alder BioPharmaceuticals Inc. on 5 of the 8 factors.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. Its clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. The company is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; and license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute. The company also has a clinical trial collaboration agreement with Merck Sharp & Dohme B.V. to evaluate ATA129 in combination with Merck anti-programmed death receptor-1 therapy and Keytruda in patients with platinum resistant or recurrent epstein-barr virus-associated nasopharyngeal carcinoma. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis. In addition, the company has preclinical programs in the discovery phase for various indications. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.